Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Santen Set to Thwart Post-Launch Challenges Expected for Myopia Drug Hopefuls: President
Santen Pharmaceutical aims to boost the value of its pipeline candidates that would drive its growth after FY2026 by countering challenges that might come along with the launch of these products. The company hopes to translate part of these efforts…
To read the full story
BUSINESS
- Regenxbio Clears Path to Resubmit Hunter Syndrome Gene Therapy
June 24, 2026
- Merck Biopharma Files Lurbinectedin for SCLC in Japan
June 24, 2026
- Sumitomo Pharma’s Average Pay Jumps on Workforce Rejig
June 24, 2026
- Nippon Shinyaku, Boston Children’s Hospital to Partner in Neurology Research
June 24, 2026
- Fycompa Generics Head for Summer Launch as Key Patent Expires
June 23, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…